betway必威登陆网址 (betway.com )学报››2022,Vol. 43››Issue (8): 596-600.DOI:10.3969/j.issn.2097-0005.2022.08.008

• 临床研究 •上一篇下一篇

子宫体原发性弥漫大B细胞淋巴瘤临床病理观察

许璇(), 仇玮, 丁瑾()

  1. 南京市江宁医院(南京医科大学附属江宁医院)病理科,江苏 南京 211100
  • 收稿日期:2022-04-06出版日期:2022-08-25发布日期:2022-09-02
  • 通讯作者:丁瑾
  • 作者简介:许璇,硕士,副主任医师,研究方向:临床病理诊断,E-mail:xuxuan20051064@163.com

Clinicopathological features of primary diffuse large B-cell lymphoma of the corpus uteri

Xuan XU(), Wei QIU, Jin DING()

  1. Department of Pathology,Nanjing Jiangning Hospital (Affiliated Jiangning Hospital of Nanjing Medical University),Nanjing 211100,China
  • Received:2022-04-06Online:2022-08-25Published:2022-09-02
  • Contact:Jin DING

摘要:

目的探讨子宫体原发性弥漫大B细胞淋巴瘤的临床病理特征、诊断与鉴别诊断、治疗和预后,提高病理诊断的准确性。方法收集本院1例子宫弥漫大B细胞淋巴瘤的临床病理学资料,结合文献对其临床表现、镜下形态特点、鉴别诊断、治疗和预后进行分析。结果患者老年女性,临床表现为绝经后阴道出血,血清乳酸脱氢酶(lactate dehydrogenase, LDH)水平升高,CT示子宫弥漫性增大伴密度不均。光镜下见肿瘤呈弥漫性生长,浸润子宫壁全层。肿瘤细胞大小较一致,体积约为正常淋巴细胞2 ~ 3倍,胞浆较少,细胞核呈圆形、卵圆形,核内有一个中位核仁或多个贴近核膜的核仁,可见核分裂象及凋亡小体。小灶区散在少量体积较大的异型瘤巨细胞,核形不规则,局灶区域见少量坏死组织。免疫组化标记肿瘤细胞CD20、Pax-5、BCL-2、BCL-6、Mum-1呈阳性表达,Ki-67阳性指数约80%,CKpan、CD10、CD3、ALK、CD30、CyclinD1、SMA、Desmin、CD99、Syn、CgA、CD56均阴性。分子检测结果示 B细胞淋巴瘤基因重排阳性,FISH检测示EBER阴性。结论子宫体原发性弥漫大B细胞淋巴瘤是一种少见的淋巴造血系统恶性肿瘤,确诊需结合镜下组织学形态、免疫标记及分子病理检测,应与高级别子宫内膜间质肉瘤、低分化子宫内膜样癌、NK/T细胞淋巴瘤、子宫淋巴瘤样病变等鉴别,综合治疗的效果较好。

关键词:子宫体,淋巴瘤,免疫组织化学,鉴别诊断,分子检测

Abstract:

ObjectiveTo investigate the clinicopathological characteristics, diagnosis, differential diagnosis, treatment and prognosis of primary diffuse large B-cell lymphoma of corpus uteri and to enhance the accuracy of pathological diagnosis of the disease.MethodsThe clinicopathological data of 1 case of corpus uteri diffuse large B-cell lymphoma in our hospital was collected, the clinical manifestations, microscopic morphological characteristics, differential diagnosis, treatment and prognosis were analyzed.ResultsThe patient was an elderly female with clinical manifestations of postmenopausal vaginal bleeding and elevated serum LDH level. CT showed diffuse enlargement of uterus and uneven density. Microscopically, the tumor showed diffuse growth and infiltration of the entire uterine wall. The tumor cells which is uniform in size, about 2 ? 3 times bigger than normal lymphocytes, showed less cytoplasm, round and oval nuclei, a median nucleoli or multiple nucleoli which is close to the nuclear membrane. Mitotic images and apoptotic bodies could be seen. Focal areas were scattered with a few of heteromorphic tumor giant cells which had irregular karyotype and necrotic tissue. Immunohistochemical tumor cells were positive for CD20, Pax-5, Bcl-2, Bcl-6 and Mum-1, Ki-67 labeling index was about 80%, CKpan, CD10, CD3, ALK, CD30, CyclinD1, SMA, Desmin, CD99, Syn, CgA and CD56 were negative. Molecular tests revealed b-cell lymphoma gene rearrangement. The tumor was found to be EBV negative by FISH assay for EBER.ConclusionThe DLBCL originating in the uterus is a rare malignant tumor of lymphoid and hematopoietic tissues, and its definite diagnosis comes from histologic morphology, immunohistochemistry and molecular detection. DLBCL should be differentiated from high grade endometrial stromal sarcoma, Grade 3 endometrioid endometrial carcinoma, NK/T cell lymphoma, lymphomatoid lesion of uterus and so on. Excellent prognosis outcomes can be achieved through comprehensive treatment.

Key words:corpus uteri,lymphoma,immunohistochemistry,differential diagnosis,molecular detection